EntreMed’s ENMD-2076 Demonstrates Antitumor Activity In Multiple Myeloma Model

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-981693, the free base of ENMD-2076. The data were presented by Dr. Xiaojing Wang, postdoctoral fellow of EntreMed collaborator Dr. Sherif S.

More: continued here

Filed under: Blood on June 10th, 2008